Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Aim: To elucidate this issue, we reassess percentage of BM blasts of MDS with erythropoiesis ≥50% from the Spanish registry (RESMD), according to both definitions.
Methods: We performed a retrospective analysis of 507 primary MDS diagnosed according to WHO 2008. Proportion of red-cells was calculated in 500 nucleated cells. Erythroid hyperplasia was documented in 10.4% of patients from RESMD.
Results: Median age of presentation was 74years (25-94years) and 63% were males. Median follow-up was 29.4 months and median OS was 47.14 months. Table 1 shows distribution of WHO subtypes of the series according to both approaches. Of note, following WHO recommendations, RAEB-2 diagnosis was not possible; formally all of them were diagnosed with erythroleukemia. Distribution of patients according to IPSS-R blast-categories by both methods is shown in Table 2. It is noteworthy that 14/389pts (3.6%) with blasts <5% using approach-A were reclassified in 10-<20% category (RAEB-2) when the approach-B was applied. However, their survival did not differ significantly from those who remained in low-count blast categories. Using approach-A, IPSS-R blast categories discriminate significantly OS of blast subgroups <5% (0-2% vs. 2-<5%, 81 vs. 44 months, p=0.011). Nevertheless, categories with ≥5% blasts showed no differences (5-10% vs. 10-20%; 18 vs. 13 months, p=0.39). With approach-B, significant differences were observed among categories with <10% blasts (0-2% vs. 2-<5% vs. 5-10%; 82 vs. 65 vs. 41 months, p=0.032). However, as in IPSS-R, no differences were observed >10% (10-20% vs. >20%; 20 vs. 14 months, p=0.53). Figure 1. Applying approach-A, significant differences in proportion of patients with high-risk karyotype defined by IPSS were seen between ≥5% blasts vs. <5%, but not between 5-<10% and 10-20%. Using approach-B, these differences appeared in 10% cut-off, without differences between 10-<20% and >20%. Therefore, high-risk patients (>10% blasts and high-risk cytogenetics) were better defined by the second method.
Conclusion: In agreement with WHO committee recommendations, these results suggest that there is no a uniform criteria for assessment of medullary blasts. Considering percentage of blasts on the basis of non-erythroid compartment might improve the classification and prognostication of MDS with ≥5% blast cells. However in low-blast count patients this approach could overestimate their risk.
Disclosures: Valcárcel: Celgene Corporation: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Amgen: Honoraria , Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau ; Novartis: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; GlaxoSmithKline: Membership on an entity’s Board of Directors or advisory committees , Speakers Bureau . Ramos: GlaxoSmithKline: Honoraria ; Janssen-Cilag: Honoraria , Membership on an entity’s Board of Directors or advisory committees ; Novartis: Consultancy , Honoraria ; Celgene Corporation: Consultancy , Honoraria , Membership on an entity’s Board of Directors or advisory committees , Research Funding ; Amgen: Consultancy , Honoraria .
See more of: Myelodysplastic Syndromes – Clinical Studies
See more of: Oral and Poster Abstracts
*signifies non-member of ASH